Introduction
The increasing rate of human immunodefi ciency virus (HIV) infection in many countries has had an impact on tuberculosis (TB) epidemiology. While TB prevalence has remained stable, TB incidence continues to rise, especially in countries most severely affected by the HIV epidemic as well as those facing political turmoil, migration, poverty and unemployment and where intravenous drug abuse is rampant. HIV is the most important known risk factor that promotes progression to active TB in people with Mycobacterium tuberculosis infection (TB/HIV A Clinical Manual 2004). The lifetime risk of tuberculosis in immunocompetent persons is 5% to 10%, but in HIV positive individuals, there is a 5% to 15% annual risk of developing active TB disease (Swaminathan et al 2000) . WHO estimated 9.2 million new cases of TB globally in 2006 (139 per 100,000); of whom 7,09,000 (7.7%) were HIV positive (World Health Organization 2008) . India, China, Indonesia, South Africa and Nigeria rank fi rst to fi fth in terms of incident TB cases.
In India, there were 2.5 million people living with HIV and AIDS (PLWHA) at the end of 2007 while the incidence of TB was approximately 1.8 million cases per year (WHO Release 2007 , RNTCP 2008 . In a survey carried out among new tuberculosis patients by the Revised National TB control Program (RNTCP) in 2007, HIV sero-prevalence
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Impact of HIV on TB manifestations
HIV infection is associated not only with an increased incidence of TB, but with altered clinical manifestations especially in the advanced stages. As HIV progresses, there is cutaneous anergy as well as impaired tissue containment of mycobacteria leading to widespread dissemination of mycobacteria. Figure 1 shows the increasing risk of tuberculosis as CD4 declines. In patients with latent TB infection, the risk of developing active disease is higher among recently infected persons compared to those with chronic infection but is several hundred-fold higher among persons who acquire HIV (fi gure 2). Further, among persons with HIV infection, newly acquired TB infection can rapidly progress to active disease.
It is clear that HIV infection acquired after TB infection is a signifi cant risk factor for development of active TB--mainly due to its effects on the immune system. HIV is associated with decreased chemotaxis, defective granuloma formation and maintenance, impaired antigen processing and presentation as well as generalized loss of CD4+ T cells and selective clonal depletion of M-TB specifi c CD4+ T lymphocytes (Lawn et al 2002) . While TB can develop at any CD4 count, extrapulmonary and disseminated forms of the disease are more common as immunodefi ciency increases.
Recently, Miranda et al (2007) demonstrated an 80% reduction in incident TB in HAART treated compared to ART-naïve HIV-infected persons in Brazil. It is likely that as access to ART improves world-wide, there will be a reduction in new TB cases, though rates would still be higher than in the general population.
Pulmonary TB
Pulmonary involvement occurs in about 75% of all HIVinfected patients with TB. (Deivanayagam et al 2001; Ahmad and Shameem 2005; TB/HIV: A Clinical Manual 2004) . Unlike other opportunistic infections which have a selective range of CD4 in which the disease occurs, TB occurs throughout the course of HIV. The interaction between HIV and TB in persons coinfected with HIV and TB is bidirectional and synergistic. Clinical presentation however depends on the level of immnuosuppression. Typical manifestations are frequent in early HIV and atypical features begin to occur as the immunity declines with more frequent extra pulmonary manifestations ranging from 46 to 79% (Kumarasamy et al 2005; Sharma et al 2005) . An HIV positive individual with any of the following symptoms should be suspected of having TB and investigated further: cough of more than 2 weeks duration, fever lasting more than CD4+lymphocyte count × 10 9 /L 2-3 weeks, weight loss, fatigue, listlessness, unexplained dyspnoea, chest pain, or hemoptysis. Accelerated weight loss defi ned as greater than 10% weight loss in a month in HIV has earned the name "slimming disease". Differential diagnoses include bacterial or fungal pneumonias, Pneumocystis Jiroveci pneumonia (PCP), lymphoma and wasting syndrome. Cough with productive mucopurulent sputum is in favour of bacterial pneumonias including 
Extra pulmonary TB
Extra pulmonary TB is the commonest cause of pyrexia of unknown origin (PUO) among HIV+ individuals in developing countries (Rupali et al 2003; Kejariwal et al 2001) . The most frequent extra pulmonary form of TB is involvement of the lymph nodes with cervical region being the commonest (Arora and Kumar 1999) . Persistent generalized lymphadenopathy (PGL) simulates TB of the nodes. In PGL, nodes are symmetrical, asymptomatic and non-tender whereas in TB, lymph nodes are usually larger, asymmetric, painless and matted and maybe associated with constitutional symptoms or mediastinal/hilar adenopathy in the chest x-ray. Intrathoracic lymphadenopathy is not a feature of primary HIV syndrome and should always the raise the suspicion of TB or lymphoma. Lymph node involvement in HIV is characterized by poor granuloma formation with abundant AFB picked up by Ziehl Neelsen stain (Havlir and Barnes 1999) Diagnosis can be easily made by FNAC (done as an out-patient procedure) or by lymph node biopsy. While Mycobacterium tuberculosis accounts for most mycobacterial infections in India, a small proportion are due to non-tuberculous mycobacteria like M. avium intracellulare, M. fortuitum etc. -molecular or high performance liquid chromatography (HPLC) assays are required to differentiate between species .The other forms of extrapulmonary TB include pleural effusion, pericardial effusion, abdominal TB, TB meningitis and abdominal TB. Pleural effusion is usually unilateral and asymmetric, may be associated with parenchymal opacities.
Intra cranial space occupying lesions are common in HIV-infected individuals: the differential diagnosis includes cerebral toxoplasmosis, tuberculoma, neurocysticercosis, cryptococcoma and lymphoma. In India, cryptococcal meningitis is the commonest form of meningitis followed by TB meningitis. A fi nding that is strongly suggestive of disseminated TB is the detection of choroidal tubercles associated with miliary TB (Sahn and Neff 1974) . Features of abdominal TB include hepatosplenomegaly with focal intra abdominal lymphadenopathy. Ascitis and omental thickening are less common in HIV (Fee et al 1995) .
Mycobacteremia has been observed to be an important cause of PUO, particularly among patients with severe immunosuppression, but is diffi cult to diagnose as it requires facilities to perform blood culture using rapid culture techniques like BACTEC (Ramachandran et al 2002) . In a study done in Africa, in patients with severe wasting at necropsy, nearly half had evidence of disseminated TB (Lucas et al 1994) .
Investigations for diagnosis of TB

Sputum examination
Three sputum specimens should be collected for patients suspected to have TB, including at least one overnight collection. Smear should be stained by Ziehl-Neelsen (conventional microscopy) or Auramine rhodamine (fl uorescent microscopy). The advantages of fl uorescence over light microscopy for the detection of pulmonary TB have been confi rmed in a systematic review of 45 studies comparing the 2 methods, which found that fl uorescence microscopy yielded an average increase in sensitivity of 10% with no loss of specifi city (Steingart et al 2006) . In situations where all 3 smears are negative, the RNTCP recommends a course of broad-spectrum antibiotics (avoiding quinolones) and repeating sputum smear examinations and performing a chest x-ray if the patient is still symptomatic for chest disease (Agarwal and Chauhan 2005) . WHO recently proposed a modifi ed algorithm for severely ill patients suggesting that anti-TB treatment can be started based on non-response to antibiotics and a chest x-ray, within 3-5 days (WHO smear negative algorithm 2006). However, this approach needs to be validated in a low HIV-prevalence country like India.
Culture (on Lowenstein-Jensen medium) is much more sensitive but takes 6-8 weeks and requires specialized laboratory facilities and trained staff. Automated liquid culture systems that detect bacterial CO 2 production or O 2 consumption with radiometric (BACTEC), fl uorescent (MGIT), colorimetric (MB/BacT system) or pressure sensors (ESP culture system II) roughly halve the time to detection and are being evaluated for use in resource-poor settings (Williams-Bouyer et al 2000; Lee et al 2003; Gil-Setas et al 2004) . Molecular assays have been developed for rapid detection of growth as well as species identifi cation and drug susceptibility testing. The 3 most widely used assays, polymerase chain reaction (PCR) (Roche Diagnostics), transcription mediated amplifi cation (Genprobe) and stranddisplacement amplifi cation (Becton Dickinson) have shown excellent sensitivity, specifi city and speed. Despite the clear advantages of these nucleic acid amplifi cation tests over existing tests, especially for the rapid detection of smear negative disease, they have only limited use in TB endemic settings, primarily because of their cost and complexity.
Chest radiography
While radiography is a commonly performed investigation, it must be remembered that patients with HIV co-infection may not have typical radiographic features of pulmonary tuberculosis. While patients with higher CD4 cells (>350 cells/mm 3 ) have radiographic abnormalities similar to their HIV negative counterparts, patients with immunosuppression often have minimal or atypical fi ndings (Long et al 1991) . Diffuse pulmonary infi ltrates/opacities are the dominant radiological presentation and cavitation is uncommon. Miliary pattern, mediastinal adenopathy and pleural effusion are more common and x-rays may be normal in 5-10% of HIV+ individuals . Differential diagnoses include PCP, non-tuberculous mycobacteria, nocardiosis, fungal infections and non-infective complications like lymphocytic interstitial pneumonitis. In the presence of a radiographic lesion suggestive of TB with negative sputum smears in an ambulatory patient, the best approach is to give a course of broad spectrum antibiotics (including co-trimoxazole) and repeat x-ray after 10-15 days. Lack of improvement or deterioration would indicate TB (TB/HIV A Clinical Manual 2004).
Tuberculin skin (Mantoux) test
Tuberculin skin reactivity is dependant on cytokine mediated cellular immunity. It has been used as a diagnostic test for tuberculosis infection: an induration of 5 mm or more, in response to 1 TU of PPD-RT 23 tuberculin is usually taken as a positive response, in HIV-infected individuals. In TB high prevalence countries like India, tuberculin skin testing has no value in TB diagnosis, as a positive test indicates prior infection only and false negativity (due to anergy or other unknown factors) is common. In a recent analysis, we found that even with the cut off of 5 mm universally practiced for TB in HIV, in India the positive predictive value of a TST for TB was 48.8% for patients with CD4 < 200 cells / mm 3 and only 18.8 for patients with CD4 > 200 cells /mm 3 . Anergy testing using polyvalent antigens like candida, tetanus toxoid, or mumps has been given up now because it is highly unreliable. Overall, tuberculin testing is not useful in routine practice either for diagnosis of TB or latent TB infection. An initially negative PPD may become positive when IRS occurs and this has been suggested as a marker for IRS (Lawn et al 2005) .
Treatment of TB in HIV positive patients
Current guidelines recommend that irrespective of HIV status, tuberculosis requires a minimum of 6 months of treatment with 4 drugs (including rifampin) in the intensive phase and 2 drugs in the continuation phase. Treatment consists of INH (H), Rifampin (RIF), Ethambutol (EMB) and Pyrazinamide (PYZ) for 2 months followed by INH and RIF for 4 months, given either daily or intermittently. In India, under the RNTCP, patients with newly diagnosed TB receive a 6-month thrice-weekly regimen (Cat I -2EHRZ 3 / 4RH 3 ) while those with relapse, default or failure receive an 8-month regimen (Cat II -2SEHRZ 3 /1EHRZ 3 /5EHR 3 ). Patients with smear negative pulmonary TB and localized extrapulmonary forms are treated with Cat III -2HRZ 3 / 4RH 3, however this regimen should be avoided in persons with HIV infection.
While there have been no randomized clinical trials comparing daily and thrice-weekly treatment, observational studies have documented a higher risk of acquired rifamycin resistance when highly intermittent regimens are used in patients with advanced HIV disease (Nahid et al 2007) . Factors that have been associated with higher failure and relapse rates along with increased mortality during treatment and follow-up are severe immunosuppression (CD4 < 100 cells/mm 3 ), highly intermittent rifampicin administration, lack of rifampicin in the regimen used and duration of treatment of < 6 months. (Ackah et al 1995; Driver et al 2001; Jindani et al 2004; Lawn et al 2007a, b; Nahid et al 2007) . The Tuberculosis Research Centre (TRC) found, in a pilot study of patients with advanced HIV and TB, a favourable response of 72% and an unfavourable response of 28% (including treatment failure and deaths) when treated with RNTCP Cat I regimen. Further, 37% of patients had died within 24 months of completing ATT. In general, HIV-infected patients with TB have higher mortality during and after treatment compared to HIV uninfected patients (Harries et al 2001; Nahid et al 2007; . An ongoing randomized clinical trial at TRC is examining the benefi ts of a longer (9-month) regimen in reducing recurrences. Wider access to anti-retroviral treatment will help reduce mortality due to HIVTB.
Anti-retroviral treatment
Currently available antiretroviral agents fall in the following groups of drugs: Nucleoside reverse transcriptase inhibitors (NRTIs), Non-nucleoside reverse transcriptase inhibitor (NNRTI's), Protease inhibitors (PI), Integrase inhibitors, Chemokine receptor antagonists and Entry (fusion) inhibitors. HAART refers to the use of a combination of at least 3 antiretroviral (ART) drugs to form a maximally suppressive regimen. Regimens recommended for use in India for patients with concomitant TB are a combination of 2 NRTI's with Efavirenz or less commonly Nevirapine. The NRTI combinations used commonly are Zidovudine with Lamivudine, Stavudine with Lamivudine, Tenofovir with Lamivudine, and rarely Abacavir with Lamivudine or Didanosine with Lamivudine (only the fi rst two combinations are available in the national program) (National AIDS Control Organization 2007) There is some preliminary data to suggest that nevirapine can be safely given with rifampicin, but results of ongoing clinical trials are awaited (Manosuthi et al 2006 (Manosuthi et al , 2008 Cohen et al 2008) . Among the PI's, nelfi navir, saquinavir, lopinavir and ritonavir can be used but additive hepatoxicity may occur with anti-TB drugs requiring close monitoring of liver function. (de Jong et al 2004) . Table 1 summarizes the WHO recommendations for timing of antiretroviral treatment initiation in HIVTB patients. In our experience, about 2/3rd of HIV infected individuals have a CD4 < 200 cells/mm 3 when they present with TB. Hence, the earlier use of ART is likely to reduce mortality and morbidity in this group of patients. Table 2 compares the advantages of early versus deferred ART in patients with TB. While the risks of IRIS and overlapping drug toxicities are present, the major advantage of early ART is the signifi cant reduction in deaths.
Rifampicin -ART interactions and cytochrome P450 -3A (CYP-3A) system
Rifamycins are unique in their ability to destroy both intracellular and intermittently and slowly growing TB bacilli and therefore form an indispensable component of anti-TB regimens. Non-Rifampicin containing regimens used to treat HIV-TB are associated with greater failure and relapse rates. (Jindani et al 2004; de Jong et al 2004) . However, Rifamycins induce the CYP-3A enzyme system in the liver and intestinal wall, thereby increasing the metabolism of PI and non-nucleoside reverse transcriptase inhibitors (table 3) . The effect is weaker with rifabutin than rifampin. Rifampin is metabolized through deacetylation and is not itself affected by the CYP-3A system. When rifampicin and antiretroviral drugs are given together, decreased trough levels may result, leading to therapeutic failure. Nevirapine levels are reduced by about 40-55%, efavirenz by 25% and delavaridine by 96% (McIlleron et al 2007) . It has been suggested that the dose of Efavirenz be increased to 800 mg when administered along with Rifampicin, but this may not be necessary in subjects weighing < 50 kg. In India, Efavirenz is the preferred drug for use in HIV-TB co infected individuals at the standard 600 mg dose. However, Nevirapine may be used in HIV-TB patients on concomitant ATT, when Efavirenz is contraindicated as in pregnancy, persons with psychiatric problems or due to toxicity. Alternatively, ATT may be modifi ed with Rifabutin replacing rifampicin with the former given at a dose of 300 mg OD twice/thrice-weekly with nevirapinebased ART.
Toxicity
The overlapping toxicities due to the drugs commonly used for HIV associated TB are shown in Drug resistance caused by malabsorption can be minimized.
Decrease in IRS
Prevents other OI's simultaneously ATT period can be used to lay a foundation for better adherence to ART
Period of Hospitalization reduced
Management of ATT toxicity is crucial for subsequent ART adherence drugs used are potentially hepatotoxic but the combination of Nevirapine and Rifampicin needs to be monitored closely. Thiacetazone should not be used in HIV+ individuals because of the risk of Stevens-Johnson syndrome. Co-trimoxazole can also produce cutaneous toxicity and has to be considered in the differential diagnosis of a skin rash. While Efavirenz can produce giddiness and sleep disturbances in the fi rst few days/weeks of administration, rarely life-threatening psychiatric manifestations (depression, suicidal tendencies) can occur which require immediate termination of the drug. Most adverse effects of drugs are mild and can be managed symptomatically.
Anti-TB drug resistance
While overall patterns of drug resistance to fi rst line anti-TB drugs are similar in HIV positive and negative patients, MDRTB is marginally higher (3-4%) in HIV positive patients with newly diagnosed TB (Swaminathan 2005) . Rifampicin mono-resistance is more common in HIV infected patients and arises independently from mutations in drug susceptible strains. The mechanism is unclear but may be due to malabsorption of anti-TB drugs. Treatment for MDR-TB should ideally be based on drug susceptibility patterns and should employ at least 3-4 new drugs. The regimen should include an aminoglycoside and be given under direct observation. A typical regimen would consist of Inj Streptomycin or Kanamycin (three times a week) along with a combination of Ofl oxacin, Ethambutol, Ethionamide, Pyrazinamide with or without Cycloserine or PAS given daily. The treatment should be continued for 18-24 months (for at least 12 to 18 months after the cultures have become negative). Outcome of MDR -TB in HIV is poor. A study from South Africa in 2003 has revealed 41% mortality among HIV-infected MDR-TB cases. In the New York study in 1996, the situation was no less different with 72% of MDR -TB cases with HIV dying during treatment. (Finlay et al 2004; Park et al 1996) . Recently, strains of M. tuberculosis labelled as extensively drug resistant (XDR) TB have emerged and spread rapidly through HIV-infected populations leading to high mortality (Andrews et al 2007) . XDRTB has been reported from India , and basically is a result of mismanagement of TB. XDRTB is practically untreatable and the best approach, therefore, is to prevent its emergence, by strengthening and supporting the TB control program.
TB-IRIS
Immune reconstitution infl ammatory syndrome (IRIS) is defi ned as transient worsening or appearance of new symptoms, signs or radiographic manifestations after initiation of HAART. Tuberculosis is the most frequent pathogen associated with IRIS, of which, lymph node enlargement is the commonest manifestation. In one study, the incidence of IRIS in TB alone was 2%, with HIV coinfection it was 7%, and in those started on HAART it was 36% (Narita et al 1998) . The median period of IRIS presentation is approximtely 4-6 weeks after starting ART, however IRIS has been observed as early as one week after starting ART. Risk factors include high viral load, very low CD4 and initiation of ART soon after TB diagnosis. In TB IRIS, fever is the most frequent symptom, along with worsening infi ltrates on chest x-ray. Other manifestations include enlargement and liquefaction of lymph nodes, appearance of fresh crops of nodes, pleural effusion, pericardial effusion, ascites, subcutaneous abscesses, expanding CNS lesions and visceral lesions (Burman and Jones 2001) . Two types of IRIS are observed (i) An unmasking of a previously latent or sub-clinical infection precipitated by HAART -induced immunologic changes occurring within 1-4 weeks of initiation of HAART (e.g.) MAC lymphadenitis, TB lymphadenitis and cryptococcal meningitis. (ii) Augmented host response to antigens present in low amounts in tissues (paradoxial response).
Risk factors for TB -IRIS include early initiation of ART within two months of starting ATT, low CD4, presence of extrapulmonary TB especially of the central nervous system, disseminated TB and high viral load (Lawn et al 2007a, b) . The pathogenesis of IRIS includes a sharp amplifi cation of Interferon-gamma producing mycobacteria-specifi c T cells along with an acute outpouring of Th1 cytokines (Borgarit 2006) . It is likely that CD4 + T cells are not the only mediators of IRIS; therefore an increase in CD4 cell count with HAART does not necessarily correlate with the development of IRIS (Manabe et al 2007) . Hypercalcemia is a strange but frequent manifestation in TB-related IRIS. It is probably related to increased production of 125 dihydroxy cholecalceferol in functioning granulomas. A simple way of demonstrating IRIS is restoration of DTH response to PPD. Interferon gamma secretion and cell mediated immune response to mycobacteria are restored leading to restoration of DTH skin test response to mycobacterial antigens. Thus HAART reverses the impact of HIV on the host granulomatous response to mycobacteria. But the rapidly compensating infl ammatory response damages the tissues that characterize IRIS. (Lawn et al 2005) The differential diagnoses include treatment failure, progression of TB, superadded infections and drug reaction. The best way to tackle IRS is to rule out and treat common, endemic causes of fever fi rst. Most IRIS responds to nonsteroidal anti-infl ammatory drugs (NSAIDS) along with continuation of ART. A course of steroids (Prednisolone 1 mg/kg body weight) tapered over 4-6 weeks may be required when fever/constitutional symptoms prevail despite NSAID treatment or life-threatening symptoms occur. Thalidomide and pentoxyfi lline have also been tried as anti-infl ammatory agents (Lawn et al 2005) . Rarely, ART needs to be terminated.
Preventive therapy (Chemoprophylaxis) for TB in India
Several randomized clinical trials in HIV-infected persons have shown that the incidence of TB can be reduced by 40-60% by preventive therapy (Woldehanna and Volmink 2004; Mohammed et al 2007) . The standard regimen is Isoniazid for 12 months, though several short-course regimens like 2RZ and 3RH have been tried and found to be equivalent. However, adverse reactions tend to be higher with multi-drug regimens and the 2RZ regimen is no longer recommended because of a high incidence of hepatotoxicity, including several fatal cases in HIV un-infected persons (Narita et al 2002) . Standard recommendations in USA, UK etc include giving preventive therapy to all PPD-positive (>5 mm) HIV positive persons, after ruling out active TB. Presently, there is no national policy regarding TB preventive therapy for HIV positive persons in India. A clinical trial being conducted at the Tuberculosis Research Centre, Chennai is investigating two different regimens: a 6-month regimen of ethambutol and INH vs. a 3-year regimen of INH alone, in order to establish the ideal duration of therapy. In a TB-endemic country like India, consideration must be given to providing preventive therapy to HIVinfected persons regardless of Mantoux status.. This is because the prevalence of TB in the community is high with a constant risk of exposure as well as the fact that the Mantoux test has many pitfalls in interpretation. TB preventive therapy should form part of the care and support package for HIV+ persons that includes co-trimoxazole prophylaxis, nutritional counseling and supplementation and anti-retroviral treatment. It needs to be delivered through integrated counseling centres or anti-retroviral treatment centres, where HIV+ individuals are followed over the long term.
Coordination between TB and AIDS control programs
At the national level, there is a concerted effort to achieve coordination between the designated microscopy centre (DMC) of the RNTCP and the integrated counselling and testing centers (ICTC) of the HIV/AIDS control program. The objective is to promote early diagnosis and treatment of TB in HIV infected individuals and vice versa. All ICTC clients with suggestive symptoms are referred by the counselor to the nearest microscopy centre for investigations to rule out TB. In 2007, approximately 5% of all diagnosed TB cases in India came from ICTCs, demonstrating that these are excellent sites for active TB case fi nding (RNTCP report 2008) . Further, the yield of cases was similar (approximately 20%) from HIV infected and uninfected clients. Counselors need ongoing training to improve their knowledge about TB diagnosis and treatment. One of the programmatic limitations encountered is the lack of investigations for extrapulmonary TB at peripheral health facilities; another is the distance between DMCs and ICTCs in some districts. The system works much better when both are located in the same site. Till a few months ago, TB patients were offered HIV testing only when the physician suspected HIV, due to coexisting symptoms or signs (selective testing). Recently, the National AIDS Control Organization has taken a decision to routinely offer HIV testing to all diagnosed TB patients in the high-prevalence states. Our study on 4000 TB patients demonstrated that over 2/3rds were willing to undergo an HIV test and the major barrier to acceptance was patients not perceiving themselves to be at risk . If patients are counseled and explained the importance of having an HIV test, when they are diagnosed with TB, most will accept the test.
With increasing availability of ART across the country, diagnosis of HIV is benefi cial to the individual as he/she can be referred to the nearest ART centre for evaluation and initiation of antiretroviral treatment, if indicated. Tuberculosis clinics, therefore, form an important entry point for HIV diagnosis, care and support. Further, the counseling that patients receive as part of the process of testing will help prevent new infections in the future. Coordination and crosstalk between these two government health programs is crucial not only to improve the outcome of HIV-infected TB patients but also to control the burden of tuberculosis in India.
